Search is Powered by Google
Cancer / Oncology News

Speedier, More Precise Cancer Radiotherapy

Main Category: Cancer / Oncology
Also Included In: Radiology / Nuclear Medicine;  Medical Devices / Diagnostics
Article Date: 08 May 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article


Current Article Ratings:

Patient / Public:not yet rated

Health Professional:5 stars

5 (1 votes)

Article Opinions: 0 posts

The University of Alabama at Birmingham (UAB) this month became the first U.S. medical center to offer a speedier cancer radiation therapy. The new technique can turn a 20-minute radiotherapy session into a 90-second session for selected patients.

Additionally, the new therapy saves healthy human tissue from unwanted radiation exposure at rates that are the same or better than other radiotherapy techniques, according to doctors at the UAB Comprehensive Cancer Center.

The new therapy is called RapidArc, which is the next-generation of intensity-modulated radiation therapy (IMRT). Conventional IMRT was introduced in the 1990s as a way to deliver multiple beams of radiation to a tumor, and minimize damage to nearby healthy tissues. RapidArc is an advancement on the earlier technology with radiation delivery times up to eight times faster than conventional IMRT, said the system's manufacturer Varian Medical Systems, Inc.

"RapidArc is an important advance for us and our patients," said John Fiveash, M.D., an associate professor of radiation oncology at UAB and Cancer Center scientist. "Knowing that we can reduce delivery times to less than two minutes per day is important considering what cancer care involves emotionally and physically."

Varian technicians added the RapidArc capability to UAB's existing IMRT machine during the last week of April. The upgrades serve as a kind of guidance system, much like a jet's automatic pilot, so that IMRT delivery can happen during a single rotation of the machine's arm around the patient.

The first U.S. patient to be given the new therapy is an Alabama man with early-stage prostate cancer whose treatment started May 6, Fiveash said. Faster radiation delivery times reduce the chances that a slight move will affect the accuracy of the radiotherapy targeting. Also, it means patients spend less time and feel less discomfort in the treatment room, he said.

"We presently treat many patients with very complex treatment plans," said John Brinkerhoff, R.Ph., M.B.A., C.M.P.E., executive administrator of UAB's Department of Radiation Oncology. "We have a head and neck cancer plan that would normally require a patient to lie still for 20 minutes with their face in a cushioned stability mask. With RapidArc, they are required to remain still for only 90 seconds."

The new system incorporates powerful computers to help doctors arrive at a radiotherapy treatment strategy after pouring over thousands of biological and mathematical variables, including medical scans of each patient's tumor.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

Source: Troy Goodman
University of Alabama at Birmingham




Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...